When do Vascepa patents expire, and what generic alternatives are available? Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. There are fifty-six patents protecting this drug and three Paragraph IV challenges.
This drug has two hundred and sixty-six patent family members in fifty countries.
The generic ingredient in VASCEPA is icosapent ethyl. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the icosapent ethyl profile page.
US ANDA Litigation and Generic Entry Outlook for Vascepa A generic version of VASCEPA was approved as icosapent ethyl by HIKMA on May 21st, 2020.
News 
Market Data 
Discover 
